Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Zevra Therapeutics, Inc. - Common Stock (NQ: ZVRA )

6.260 +0.210 (+3.47%)
Streaming Delayed Price Updated: 12:51 PM EDT, Jul 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 164,322
Open 6.040
Bid (Size) 6.240 (2)
Ask (Size) 6.270 (2)
Prev. Close 6.050
Today's Range 5.859 - 6.330
52wk Range 3.890 - 7.280
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Insiders Buying Zevra Therapeutics And 1 Other Stock
Via Benzinga
Insiders Buying Barnes & Noble Education And 2 Other Stocks
Via Benzinga

Performance

YTD
-8.35%
-8.35%
1 Month
+43.58%
+43.58%
3 Month
+36.98%
+36.98%
6 Month
+4.86%
+4.86%
1 Year
+31.24%
+31.24%

More News

Read More
SmallCap Tech/Biotech Stocks July/Aug 2024: ZVSA, DYAI, ZVRA, PRSO, RLMD, VTAK, ENTO, INBS, KAVL
Via AB Newswire
FDA Convenes Expert Panel Meeting For Zevra Therapeutics' Arimoclomol, Analyst Optimistic About Approval Despite Small Patient Base
Via Benzinga
Exposures Product Safety
ZVRA Stock Earnings: Zevra Therapeutics Beats EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Zevra Therapeutics: Q4 Earnings Insights
Via Benzinga
Earnings Outlook For Zevra Therapeutics
Via Benzinga
Zevra Therapeutics's Earnings: A Preview
Via Benzinga
Zevra Therapeutics's Earnings: A Preview
Via Benzinga
A Preview Of Zevra Therapeutics's Earnings
Via Benzinga
Zevra Therapeutics, Inc. (NASDAQ: ZVRA) Letter to Stakeholders Looks Like Launch Code to Drive Value
Via Investor Brand Network
ZEVRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Zevra Therapeutics, Inc. on Behalf of Zevra Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Zevra Therapeutics, Inc. (ZVRA)
From Kirby McInerney LLP
Via GlobeNewswire
ZVRA Stock Earnings: Zevra Therapeutics Misses EPS, Beats Revenue for Q4 2023
Via InvestorPlace
Earnings Scheduled For March 28, 2024
Via Benzinga
Microsoft To Rally Over 20%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
BioMedNewsBreaks – Zevra Therapeutics Inc. (NASDAQ: ZVRA) Resubmits Arimoclomol New Drug Application to the FDA
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks — Zevra Therapeutics Inc. (NASDAQ: ZVRA) Names New President, CEO and Director
Via Investor Brand Network
Topics Retirement
Exposures Pension
Earnings Scheduled For November 7, 2023
Via Benzinga
Health Care Company Zevra Therapeutics Announces Merger With Acer Therapeutics
Via Benzinga
Why Is Acer Therapeutics Stock Trading Higher Today?
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Acer Therapeutics Inc. (Nasdaq - ACER), Sovos Brands, Inc. (Nasdaq - SOVO), Computer Task Group, Incorporated (Nasdaq - CTG), Decibel Therapeutics, Inc. (Nasdaq -
From Brodsky & Smith LLC
Via GlobeNewswire
Why Is Acer Therapeutics (ACER) Stock Up 85% Today?
Via InvestorPlace
Earnings Scheduled For August 14, 2023
Via Benzinga
Earnings Scheduled For May 15, 2023
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.